NFKB1 and neoplasm: While no NF-κB inhibitor is clinically approved for this purpose, the encouraging results from the first-in-human study of GADD45β/MKK7 inhibitors suggest that the myeloid-associated GADD45β-dependent checkpoint will be similarly amenable to therapeutic intervention for re-programming TAMs to unleash TME-based inflammation and redirect CD8+ T-cell trafficking into tumours.